GENETIC TECHNOLOGIES LIMITED — Interim / Quarterly Report 2013

Feb 25, 2013

==> picture [295 x 175] intentionally omitted <==

GENETIC TECHNOLOGIES LIMITED

A.B.N. 17 009 212 328

Appendix 4D of the ASX Listing Rules for the half-year ended

31 DECEMBER 2012

GENETIC TECHNOLOGIES LIMITED

CORPORATE DIRECTORY

Directors

Dr. Malcolm R. Brandon (Non-Executive Chairman) Tommaso Bonvino Dr. Mervyn Cass Benjamin Silluzio

Company Secretary

Thomas G. Howitt

Registered and Head Office

60-66 Hanover Street Fitzroy Vic. 3065 Australia

Telephone: +61 3 8412 7000 Facsimile: +61 3 8412 7040 Email: info@gtglabs.com

Share Registry

Computershare Investor Services Pty. Ltd. Yarra Falls, 452 Johnston Street Abbotsford Vic. 3067 Australia

Bankers

National Australia Bank Limited Level 2, 151 Rathdowne Street Carlton Vic. 3053 Australia

Telephone: +61 3 9415 5000 Facsimile: +61 3 9473 2500

www.computershare.com

Bank of America, N.A. 155 Town Centre Drive Charlotte NC 28117 United States of America

Auditors

PricewaterhouseCoopers Chartered Accountants Freshwater Place 2 Southbank Boulevard Southbank Vic. 3006 Australia

Company Website address

Stock Exchange information

Australian Securities Exchange (code: GTG ) 2 The Esplanade Perth W.A. 6000 Australia

NASDAQ Capital Market (ticker: GENE) One Liberty Plaza, 165 Broadway New York NY 10006 United States of America

www.gtglabs.com

GENETIC TECHNOLOGIES LIMITED

APPENDIX 4D OF THE ASX LISTING RULES FOR THE HALF-YEAR ENDED 31 DECEMBER 2012

(This information should be read in conjunction with the Company’s 30 June 2012 Annual Report)

1. The reporting period covers the half-year ended 31 December 2012. The previous corresponding period covers the half-year ended 31 December 2011.

2. Results for announcement to the market

   • 2.1 Total revenues from ordinary activities for the reporting period were $5,453,090, an increase of $1,470,248, or 37%, over the figure for the previous corresponding period of $3,982,842.

   • 2.2 The comprehensive loss from ordinary activities after income tax attributable to Members for the reporting period was $3,724,377, being an increase of $401,867, or 12%, over the figure for the previous corresponding period of $3,322,510.

   • 2.3 The comprehensive loss attributable to Members for the reporting period was $3,724,377, being an increase of $401,867, or 12%, over the figure for the previous corresponding period of $3,322,510.

   • 2.4 The Company does not propose to pay a dividend.

   • 2.5 Not applicable.

   • 2.6 The increase in total revenues during the period under review was primarily due to an increase in revenues generated from the granting of licenses by the Company to its non-coding technology. The increase in the comprehensive loss attributable to Members for the reporting period was largely attributable to an increase in selling and marketing expenses associated with the Company’s expansion in the USA with its BREVAGen[TM] test.

3. The net tangible assets per ordinary share as at 31 December 2012 was 2.04 cents, being a decrease of approximately 35% over the figure for the previous corresponding period (30 June 2012) of 3.14 cents.

4. During the half-year ended 31 December 2012, Genetic Technologies Limited neither gained, nor lost, control of any other entity.

5. No dividends were paid by Genetic Technologies Limited during or after the reporting period, nor were any paid during the previous reporting period.

6. The Company has no dividend reinvestment plans in operation.

7. As at 31 December 2012, Genetic Technologies Limited held a 45.0 percent direct equity interest in ImmunAid Limited.

8. Not applicable.

9. The attached Half-Year Financial Report for the period ended 31 December 2012 contains an independent auditor’s review report which includes an emphasis of matter paragraph in regard to the existence of a material uncertainty that may cast significant doubt about the Company’s ability to continue as a going concern. Additional disclosure has been included in Note 1 to the financial statements.

Signed on behalf of Genetic Technologies Limited

Dated this 22[nd] day of February, 2013

DR. MALCOLM R. BRANDON Non-Executive Chairman